Chronic Myeloid Leukemia

Biomarkers of Imatinib Resistance in Chronic Myeloid Leukemia

With oncology pivotal trials averaging $32 million and a 95% drug failure rate, there is a growing interest in leveraging biomarkers for treatment optimization. Notably, drug resistance biomarkers are key in identifying treatment sensitivity, adjusting treatment protocols, and improving survival rates.

0 min read
Written by
Elizabeth Bolitho
  • Categories
  • Biomarkers
Receive the latest newsletter directly to your inbox

Leveraging Biomarkers for Treatment Optimization

Drug Resistance Biomarkers

Biomarker Identification and Prioritization

Biomarkers of Imatinib Resistance in Chronic Myeloid Leukemia image 0
Figure 1: Percentage of imatinib resistance biomarkers for CML by target class.

Conclusions

References

More on Biomarkers